deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06155383

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

A Phase II Study of Perioperative Disitamab Vedotin Plus Toripalimab and XELOX Versus Disitamab Vedotin Plus Toripalimab Versus XELOX in Subjects With HER2-expressing Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Sponsor: RemeGen Co., Ltd.

Conditions Gastric Cancer Gastroesophageal Junction Adenocarcinoma
Interventions Capecitabine Disitamab Vedotin Toripalimab oxaliplatin
Updated 3 times since 2024 Last updated: Dec 12, 2023 Started: Nov 27, 2023 Primary completion: Jan 31, 2025 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by RemeGen Co., Ltd. and has accumulated 3 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RemeGen Co., Ltd.
Data source: RemeGen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations